ReviewLung
Prevention and treatment of bronchopulmonary dysplasia: contemporary status and future outlook.
Review in Lung. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 64 citations in OpenAlex.
- Docosahexaenoic Acid Supplementation in Postnatal Growth Restricted Rats Does Not Normalize Lung Function or PPARγ Activity.Biomolecules · 2025Article
- Postnatal growth restriction impairs rat lung structure and function.Anatomical record (Hoboken, N.J. : 2007) · 2025Article
- It takes two peroxisome proliferator-activated receptors (PPAR-β/δ and PPAR-γ) to tango idiopathic pulmonary fibrosis.Respiratory research · 2024Article
- Role of Myeloperoxidase, Oxidative Stress, and Inflammation in Bronchopulmonary Dysplasia.Antioxidants (Basel, Switzerland) · 2024Review
- Complicated Intubations are Associated with Bronchopulmonary Dysplasia in Very Low Birth Weight Infants.American journal of perinatology · 2023Article
- Review
- Hippocampal epigenetic and insulin-like growth factor alterations in noninvasive versus invasive mechanical ventilation in preterm lambs.Pediatric research · 2021Article
- Enhancing Cystic Fibrosis Immune Regulation.Frontiers in pharmacology · 2021Article
- Bronchopulmonary Dysplasia: Crosstalk Between PPARγ, WNT/β-Catenin and TGF-β Pathways; The Potential Therapeutic Role of PPARγ Agonists.Frontiers in pediatrics · 2019Review
- Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment.Lung · 2018Review
- 5-aza-2'-deoxycytidine, a DNA methylation inhibitor, attenuates hyperoxia-induced lung fibrosis via re-expression of P16 in neonatal rats.Pediatric research · 2018Article
- Article
- Influence of prenatal hypoxia and postnatal hyperoxia on morphologic lung maturation in mice.PloS one · 2017Article
- On the evolution of the pulmonary alveolar lipofibroblast.Experimental cell research · 2016Review
- Article
- Homeostasis as the Mechanism of Evolution.Biology · 2015Article
- Epigenetic contributions to the developmental origins of adult lung disease.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2015Review
- Role of microRNA-150 and glycoprotein nonmetastatic melanoma protein B in angiogenesis during hyperoxia-induced neonatal lung injury.American journal of respiratory cell and molecular biology · 2015Article
- The lung alveolar lipofibroblast: an evolutionary strategy against neonatal hyperoxic lung injury.Antioxidants & redox signaling · 2014Review
- Curcumin protects the developing lung against long-term hyperoxic injury.American journal of physiology. Lung cellular and molecular physiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Despite tremendous advances in neonatology, bronchopulmonary dysplasia (BPD) remains a major cause of morbidity and mortality among premature infants. Any intervention that would reduce the risk of BPD or improve its outcome is likely to have substantial clinical and financial benefits. However, there is a clear lack of an effective agent for the treatment and/or prevention of BPD. This is due to an incomplete understanding of the molecular mechanisms involved in its pathogenesis. Taking a basic biological approach, our laboratory has discovered that disruption of normal alveolar homeostatic signaling is centrally involved in this process. Using a number of in vitro and in vivo models, our laboratory has demonstrated that stabilization of the normal alveolar homeostatic signaling pathway(s) can prevent and/or rescue the molecular injuries caused by the insults that lead to BPD. Here, we review the existing approaches to prevent and treat BPD and then, based on our insights into the pathogenesis of BPD, we propose novel and innovative therapeutic options that impact the disease on a cell/molecular level, unlike most of the current treatments available for BPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.